Cytosorbents (NASDAQ:CTSO) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I

Cytosorbents (NASDAQ:CTSO) was upgraded by stock analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.

Other equities analysts have also issued reports about the stock. B. Riley reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Cytosorbents in a research report on Wednesday, May 15th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Tuesday, May 7th. Finally, StockNews.com started coverage on shares of Cytosorbents in a research report on Monday. They issued a “hold” rating for the company.

Cytosorbents Stock Performance

CTSO stock opened at $1.19 on Monday. The firm has a market cap of $64.36 million, a price-to-earnings ratio of -2.01 and a beta of 0.58. The firm has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $0.93. Cytosorbents has a one year low of $0.70 and a one year high of $3.73. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $9.79 million during the quarter, compared to analyst estimates of $9.78 million. Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. During the same period in the prior year, the firm posted ($0.17) earnings per share. On average, equities analysts forecast that Cytosorbents will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently bought and sold shares of the business. Key Client Fiduciary Advisors LLC increased its holdings in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares during the period. Raymond James & Associates acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $56,000. CM Management LLC grew its stake in shares of Cytosorbents by 98.8% during the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after purchasing an additional 410,000 shares during the period. Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the period. Finally, Neuberger Berman Group LLC grew its stake in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.